ProBio is an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven trial in patients with metastatic prostate cancer
Joined January 2019
- Tweets91
- Following0
- Followers148
- Likes27
Pinned Tweet
📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.
🤖 Made with AI
📣 Published in @EUplatinum : our Letter to the Editor on the @myESMO Clinical Practice Guideline for advanced and metastatic prostate cancer.
⚕️The guideline notes the lack of mCRPC trials comparing ARPI with docetaxel-based chemotherapy
🌐doi.org/10.1016/j.eururo.202…
🎯By integrating liquid biopsy profiling, multi-arm platform methodology, patient-reported outcomes, and international collaboration, ProBio-mHSPC seeks to move from “one-size-fits-all” towards more precise, evidence-based care.
🙏 A sincere thank you to all participating patients, sites, investigators, clinical teams, collaborators, companies and funders supporting this effort.
#ProstateCancer #ClinicalTrials #PrecisionOncology #LiquidBiopsy #ctDNA #mHSPC #Oncology #Urology #PersonalizedMedicine
🚨 New Study Alert! 🚨
What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC
A thread 🧵👇 #CancerResearch #ProstateCancer
[1/8]
What’s next?
🏥 @ProBioTrial will explore treatment de-escalation for low-ctDNA patients
🔬 Future trials should integrate ctDNA fraction 🩸🧬 as a stratification tool
👨⚕️ ctDNA may guide guide #PrecisionMedicine in all #ProstateCancer patients?
[7/8]
This research was made possible by the support of:
@ALFmedicin , @Cancerfonden , Radiumhemmet Research Funds, @Prostatacancerforbundet, @Vetenskapsradet , Krebsliga beider Basel, & @KomOpTegenKanker
THANK YOU! 🙏
[8/8]
#CancerResearchMatters
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
ProBio retweeted
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j
ProBio retweeted
Don’t forget the @ProBioTrial is an investigator-initiated trial! Crazy level of commitment of everyone involved.
Meet the @ProBioTrial consortium: healthcare professionals from 🇸🇪🇧🇪🇳🇴🇨🇭specialised in the treatment of men with metastatic #ProstateCancer
They made the 🥈#ProBioTrial International Investigator’s Meeting a success 🙏
Presentations soon available on probiotrial.org
